

Can selenite be an ultimate inhibitor of Ebola and other viral infections?

ABSTRACT

It is known that the virulence of Ebola and other RNA enveloped viruses involves in the first step their attachment to host cell membranes. Following this initial step the virus enters the target cell cytoplasm by forming hydrophobic spikes that make holes in the membrane lipid bilayer. Formation of such spikes is catalyzed by the reduced form of viral protein disulfide isomerase (PDI_{red}) thus initiating chain of disulfide exchange reactions. Consequently, hydrophobic protein epitopes become exposed, which in the absence of proper chaperones form hydrophobic 'spikes' capable of penetrating the host cell membranes. In this communication evidence is discussed showing that the chain of disulfide exchange events can be inhibited by a small redox molecule – sodium selenite. It is suggested that this inexpensive and readily available food supplement can be an ultimate inhibitor of Ebola and other enveloped viral infections.

Key words: Ebola virus, hydrophobicity, protein disulfide exchange, sodium selenite

Introduction

Selenium (Se) is a ubiquitous element that participates in various biochemical reactions in human body. This metalloid, akin to sulfur, is present in numerous proteins forming so-called mixed disulfides [1] that participate in thiol-disulfide exchange reactions [2]. Although physiological function of selenium compounds is not well known, it has been recognized that Se deficiency is associated with certain degenerative diseases[3, 4]. However, not all Se derivatives are biologically active, and amongst various inorganic forms of Se, the best studied is its four-valent (selenite) that readily interacts with protein sulfhydryls (*P*-SH). Selenite can also interfere with and/or modify thiol/disulfide exchange reactions, particularly those occurring during the attachment of viral glycoproteins to the host cell membranes catalyzed by protein disulfide isomerase (PDI). Therefore, this specific form of inorganic selenium, which



28 inexpensive and readily available as a food supplement, can be used as an effective inhibitor of
29 Ebola and other enveloped virus infections.


30 **Disulfide exchange reactions in human proteins**

31 Properties and functions of native proteins are maintained by intra-molecular disulfide bonds that
32 are positioned in such a way as to hide hydrophobic regions inside their tertiary structure[5].

33 However, when one or more of the disulfides is reductively cleaved, the hydrophobic groups of
34 polypeptide chain(s) are unmasked and allow them to react readily one with another [6].

35 Consequently, in the absence of proper chaperones the unfolded polypeptide chains become
36 incorrectly refolded with the formation large hydrophobically bonded aggregates (Fig.1).

37



38
39 Figure 1 shows that the limited reduction of plasma proteins results in the formation of large
40 aggregates that are not dissociable during gel electrophoresis and that are remarkably resistant to


dissolution by chaotropic solvents and proteolytic enzymes. We have previously shown that similar insoluble aggregates are formed from fibrinogen under the reductive influence of iron-generated hydroxyl radicals [7] that was suggested to form a protective coat (parafibrin) around the tumor cells and prevent their elimination by NK cells [8]. It is important for this paper to note that the formation of parafibrin was demonstrated by us to be preventable by sodium selenite and other oxidizing agents [9]. The unfolded polypeptides can also form complexes with the hydrophobic tails of lipid molecules forming holes in the cell membrane bilayer [10]. It is generally believed that this mechanism is responsible for the virus entry into the host cytoplasm thus allowing its survival and multiplication [11].

It is well established that RNA-virus multiplication starts with a critical event of its attachment to the host cell membrane followed by virus entry into the cell [12, 13, 14]. To achieve this goal **Ebola and other double-stranded RNA virus** are equipped with a relatively simple albeit not obvious mechanism involving modulation of *gp120* glycoprotein moiety [15]. After the initial viral contact with the host cellular membrane a number of enzymes are activated that lead to the reduction of at least one disulfide bond in the *gp120* molecule [16, 17, 18]. Importance of this reaction for the human HIV infection was demonstrated in experiments with the use of agents that interfered with the thiol/disulfide interchange [19]. So far, two enzymes were shown to be of importance in this exchange, namely protein disulfide isomerase (PDI) [20,21], and thioredoxin reductase (Trx-R) [22, 23].

Selenium and its therapeutic potential

Selenium (Se) is a ubiquitous albeit not uniformly distributed element in the soil of various regions of Earth [24]. It is generally known that Se deficiency, both in the agricultural food products and in the human organism, is associated with various degenerative diseases, notably in viral infections [25,26,27]. In view of the fact that supplementation with this element proved to be beneficial for human health e.g. Keshan disease in China [28], numerous studies have been undertaken to document beneficial effects of Se in human pathology. However, so far no unequivocal results have been reported, most likely because there is very little understanding of the relationship between chemical forms of Se and its biological activity.

There are two classes of selenium compounds – inorganic and organic. In the former, the element occurs as a four-valent (Se^{4+}) and six-valent (Se^{6+}) cations. In the organic compounds selenium exists as selenide mostly in the form of selenocysteine. In human body there are several selenoproteins, the function of which is not clearly understood. It should be, however, strongly emphasized that the biological activity of inorganic forms of Se depends on their electronic structure. Thus, only Se^{4+} (selenite) but not Se^{6+} (selenate) is a redox active entity. This basic chemical fact is a source of misunderstanding when researches lump all forms of Se and just label them ‘selenium’. It should be born in mind that only *four-valent* Se in the form of sodium selenite can interact with free sulhydryl (-SH) groups of proteins to oxidize them to disulfides according to the following formula:



P stands for protein polypeptide chain, and Se^{2+} is the reduced form of selenite. This chemical equation is applicable to the mechanism by which selenite inhibits thiol/disulfide exchange initiated by the viral PDI (Fig.2).




Fig.2

The chain of events depicted in Fig.2 starts with the PDI-catalyzed reduction of protein disulfides in the virus glycoprotein that opens up its hydrophobic epitopes. In the absence of specific chaperones the hydrophobic “spike” of gp120 makes a hole in the host bilayer membrane through which the virus can enter into the host cytoplasm with all its pathological consequences.

91 The most effective way to prevent this event is by inhibition of protein disulfide reduction that
 92 can readily be achieved with a timely administration of *sodium selenite*. This concept provides
 93 an explanation, however tentative, why Se deficiencies are associated with enhanced infectivity
 94 of Ebola and other viruses [29]. Additionally, it is of interest to note that selenite inhibits TrxR
 95 activity in a dose dependent manner [30], and at the same time increases NK cells potency [31].
 96 The latter may explain the fact that those ca. 30 percent of people who are resistant to Ebola
 97 infections may have adequate blood concentrations of selenite and/or other electrophilic
 98 substances that can inhibit disulfide exchange and/or activate NK cells. An important argument
 99 in favor of the importance of PDI activation in virus infections is the recently reported finding
 100 that the inhibition of protein disulfide exchange prevents thrombo-hemorrhagic events so
 101 characteristic for the Ebola-induced disease [32,33].

102 Of note, another small molecule, melatonin, was recently suggested as a potential therapeutic
 103 agent in Ebola virus infections [34]. In addition to this hormone's main functions in sleep and
 104 circadian rhythm regulations, melatonin is known to scavenge hydroxyl radicals by virtue of
 105 aromatic hydroxylation [35,36]. Hence it is possible that PDI-catalyzed disulfide exchange
 106 reaction involves intermediate free radicals vulnerable to the scavenging action of melatonin
 107 [37].

108 In view of the fact that sodium selenite is readily available as an inexpensive food supplement,
 109 the concept presented in this article is particularly important for the protection of large
 110 populations against threat of Ebola epidemics [38]. However, unjustified fear of selenite
 111 "toxicity" has to be overcome, with the understanding that not all forms of this chemical exhibit
 112 similar beneficial health effects. Although small doses of 100 µg/day of sodium selenite were
 113 reported to increase the rate of poliovirus clearance, they may not be sufficient to prevent other
 114 viral infections [39, 40]. Other researchers have also reported that larger than recommended
 115 doses of sodium selenite including continuous *i.v.* infusions were well tolerated by humans [41,
 116 42] and by experimental animals [43]. However, it has to be noted that sodium selenite should
 117 not be administered together with ascorbic acid, because this vitamin reduces selenite to an
 118 inactive divalent selenium ion.

119 Finally, it is not surprising albeit not immediately obvious that sodium selenite has been used to
 120 in the prevention and/or treatment of various forms of cancer [44, 45]. Similarly to viral PDI,

selenite inhibits disulfide exchange reactions in plasma proteins (specifically fibrinogen) and in this way prevents the formation of a hydrophobic protective coat around tumor cells [8].

Conclusions

In spite of enormous complexity of biology and pathology of Ebola and other enveloped RNA viruses, there is one reaction that deserves our closer attention. This is the attachment of viral gp120 glycoprotein, which initiates the fusion and entry of virus to the host cell. This process is controlled by a redox modulation of protein disulfide exchange that can be a target for antiviral therapies. In this article evidence is presented that a specific chemical form of selenium, sodium selenite, may offer an effective weapon against Ebola and other viral infections by the inhibition of thiol/disulfide exchange reactions thus preventing virus entry and proliferation. Although this article reveals only tip of the iceberg, it is hoped that it will stimulate research efforts aimed at preventing the emerging threat of Ebola virus epidemics by the use sodium selenite and other redox-active molecules.

Legend to figures:

Fig.1.

Agarose-gel electrophoretic pattern of human plasma incubated at 37°C with a reducing agent *dithiothreitol* at various times from 0 (line 1) to 30 min. (line 7). This figure shows that the reduction of disulfide bonds in plasma proteins results in a time-dependent formation of huge hydrophobic aggregates that are not dissociable in the electric field. Other experiments (data not shown) have revealed that such aggregates are remarkably resistant the proteolytic degradation.

Fig.2.

Chain of events initiated by viral protein disulfide isomerase (PDI_{red}). It should be noted that a singular event of the withdrawal of two electrons from the sulfhydryl groups of PDI_{red} and their transfer to the selenite cation (Se⁴⁺) results in the inhibition of protein disulfide reduction in the gp120 molecules and subsequently prevents the formation of a hydrophobic spike.

REFERENCES

1. Wessjohann , L.A., Schneider, A., Abbas, M. and Brandt, W. (2007). Selenium in chemistry and biochemistry in comparison to sulfur. *Biol. Chem.* **388**,997–1006.
2. Hondal, R.J., Marino, S.M. and Gladyshev, V.N. (2013). Selenocysteine in thioldisulfide-like exchange reactions. *Antioxid. Redox Signal.***18**,1675–1689.
3. Rayman, M.P. (2000). The importance of selenium to human health. *Lancet*, **356**, 233-234.
4. Lipinski, B. and Egyud, L.G.(1992).Thiol-induced crosslinking of human blood proteins. Implications fortumor immunity. *Bioorg. Med. Chem. Lett.* **2**, 919-924.Jackson, M.J., Broome, C.S. and McArdle, F.(2003). Marginal dietary selenium intakes in the UK: Are there functional consequences? *J.Nutr.* **133**, 1557S-1559S.
5. Anfinsen, C.B. (1973). Principles that govern the folding of protein chains. *Science*, **181**,223-30.
6. Lipinski, B. and Egyud, L.G.(1992).Thiol-induced crosslinking of human blood proteins. Implications fortumor immunity. *Bioorg. Med. Chem. Lett.***2**, 919-924.
7. Lipinski, B.and Pretorius E. (2012). Novel pathway of iron-induced blood coagulation: implications for diabetes mellitus and its complications. *Pol. Arch. Med. Wewn.***122**,115-122.
8. Lipinski, B. (2014). Cancer wars: significance of protein unfolding and its inhibition with natural amphiphilic substances. *Front.Oncol.* doi:10.3389/fonc.2014.00183.
9. Pretorius, E., Bester, J., Vermeulen, N. and Lipinski, B. (2012). Oxidation inhibits iron-induced blood coagulation. *Curr. Drug Targets*,**14**, 13-19.
10. Stahelin, R.V. (2014).Membrane binding and bending in Ebola VP40 assembly and egress. *Front. Microbiol.* **5**,300. Doi: 10.3389/fmicb.2014.00300.
11. Abell, B.A. and Brown, D.T. (1993). Sindbis virus membrane fusion is mediated by reduction of glycoprotein disulfide bridges at the cell surface. *J. Virol.* **67**, 5496–5501.
12. Eckert, D.M. and Kim, P.S. (2001). Mechanisms of viral membrane fusion and its inhibition. *Annu. Rev. Biochem.* **70**,777–810. doi: 10.1146/annurev.biochem.70.1.777.
13. Hofmann-Winkler, H., Kaup, F. and Pohlann, S. (2012). Host cell factors in filovirus entry: Novel players, new insights. *Viruses*, **4**, 3336-3362.
14. Matthias, L.J. and Hogg, P.J. (2003). Redox control on the cell surface: implications for HIV-1 entry. *Antioxid. Redox Signal.***5**,133–138. doi: 10.1089/152308603321223621.
15. Stantchev, T.S., Paciga, M., Lankford, C.R., Schwartzkopff, F., Broder, C.C. and Clouse, K.A. (2012). Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection. *Retrovirology*,doi: 10. 1186/1742-4690-9-97.
16. Markovic, I., Stantchev, T.S., Fields, K.H., Tiffany, L.J., Tomic, M., Weiss, C.D., Broder, C.C., Strebel, K. and Clouse, K.A. (2004). Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. *Blood*, 103,1586-94.
17. Zhou, Y. and Simmons, G. (2012). Development of novel entry inhibitors targeting emerging viruses. *Expert Rev. AntiInfect. Ther.***10**, 1129-1138.
18. Diwaker, D., Mishra, K.P. and Ganju, L. (2013). Potential roles of protein disulfide isomerase in viral infections. *ActaVirol.***57**, 293-304.
19. Ryser, H.J., Levy, E.M., Mandel, R. and Disciullo, G.J.(1994). Inhibition of human immunodeficiency virus infection by agents that interfere with thioldisulfide interchange upon virus-receptor interaction. *Proc. Natl. Acad. Sci.USA*, **91**, 4559–4563.

20. Khan, H.A. and Mutus, B. (2014). Protein disulfide isomerase a multifunctional protein with multiple physiological roles. *Front. Chem.* Doi: 10.3389/fchem.2014.00070.
21. Dickerhof, N., Klefmann, T., Jack, R. and McCormick, S. (2011). Bacitracin inhibits the reductive activity of disulfide isomerase by disulfide bond formation with free cysteines in the substrate-binding domain. *FEBS J.* **278**, 20134-43.
22. Reiser, K., François, K.O., Schols, D., Bergman, T., Jörnvall, H., Balzarini, J., Karlsson, A. and Lundberg, M. (2012). Thioredoxin-1 and protein disulfide isomerase catalyze the reduction of similar disulfides in HIV gp120. *Int. J. Biochem. Cell. Biol.* **44**, 556-62.
23. Yoshihara, E., Masaki, S., Matsuo, Y., Chen, Z., Tian, H. and Yodoi, J. (2013). Thioredoxin/Txnip:redoxisome, as a redox switch for the pathogenesis of diseases. *Front. Immunol.* Doi: 10.3389/fimmu.2013.00514.
24. Cowgill, U.M. (1985). The distribution of selenium and cancer mortality in the continental US. *Biol. Trace Elem. Res.* **5**, 345-361.
25. Beck, M.A., Levander, O.A. and Handy, J. (2003). Selenium deficiency and viral infection. *J. Nutr.* **133**, 1463S-1467S.
26. Dworkin, D.M. (1994) Selenium deficiency in HIV infections and the acquired immunodeficiency syndrome (AIDS). *Chem Biol Interact.* **91**, 181-6.
27. Harthill, M. (2011). Review: micronutrient selenium deficiency influences evolution of some viral infectious diseases. *Biol. Trace Elem. Res.* **143**, 1325-36.
28. Chen J. An original discovery: selenium deficiency and Keshan disease (an endemic heart disease). *Asia Pac J Clin Nutr.* 2012;21:320-6.
29. Gill, H. and Walker, G. (2008). Selenium, immune function and resistance to viral infections. *Nutr Diet.* 65(Suppl 3), S41-S47.
30. Huang F., Huang, J., Lv, Q., Yang, Y., Wu, G. and Xu, C. (2013). Selenite induces apoptosis in colorectal cells through interaction with thioredoxin reductase. *BMB Rep.* pii: 2370
31. Kiremidjian-Schumacher, L., Roy, M., Wiche, H.I. and Stotzky, G. (1996). Supplementation with selenium augments the function of natural killer and lymphokine-activated killer cells. *Biol. Trace Element Res.* **52**, 227-39.
32. Flaumenhaft, R., Furie, B. and Zwicker, J.I. (2014). Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease. *Arterioscler. Thromb. Vasc. Biol.* pii: ATVBAHA.114.303410.
33. Mor-Cohen, R. (2014). Disulfide bonds as regulators of integrin function in thrombosis and hemostasis. *Antioxid. Redox Signal.* 2014 Oct 14
34. Tan, D.X., Reiter, R.J. and Manchester, L.C. (2014). Ebola virus disease: Potential use of melatonin as a treatment. *J. Pineal Res.* 2014 Sep 27. doi: 10.1111/jpi.12186.
35. Galano, A., Tan, D.X. and Reiter, R.J. (2013). On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. *J. Pineal Res.* **54**, 245-57. doi: 10.1111/jpi.12010.
36. Lipinski, B. (2011). Hydroxyl radical and its scavengers in health and disease. *Oxid. Med. Cell Longev.* DOI: 10.1155/2011/809969.
37. Hudson, D.A., Gannon, S.A. and Thorpe, C. Oxidative protein folding: From thiol-disulfide exchange reactions to the redox poise of the endoplasmic reticulum. *Free Radic. Biol. Med.* pii: S0891-5849(14)00354-2. doi: 10.1016/j.freeradbiomed.2014.07.037
38. Sanmartin, C., Plano, D., Font, M. and Palop, J.A. (2011). Selenium and clinical trials: new therapeutic evidence for multiple disease. *Curr. Med. Chem.* **18**, 4635-50.

39. Manzanares, W. and Hardy, G. (2009). Selenium supplementation in the critically ill: posology and pharmacokinetics. *Curr. Opin. Clin. Nutr. Metab. Care*,**12**, 273-80.
40. Cermelli, C., Vincenti, M., Scaltriti, E., Bazzani, E., Beretti, F., Vivoli, G. and Portolani M. (2002). Selenite inhibition of Cocksackie virus B5 replication; implications on the etiology of Keshan disease. *J.TraceElem.Med.Biol.***16**, 41-6.
41. Burk, R.F., Nortsworthy, B.K., Hill, K.E., Motley, A.K. and Byrne, D.W. (2006). Effects of chemical forms of selenium on plasma biomarkers in high-dose human supplementation trial. *Cancer Epidemiol. Biomarkers Prev.***15**, 804-810.
42. Forceville X. (2013). The effect of selenium therapy on mortality in patients with sepsis syndrome: simple selenium supplementation or real (5 H₂O)·Na₂SeO₃ pharmacological effect?*Crit Care Med.* **41**,1591-2. doi: 10.1097/CCM.0b013e31829106e5.
43. Bhattacharya, R.S., Husbeck, B., Feldman, D. and Knox, S.J. (2008). Selenite treatment inhibits LACP-4 tumor growth and prostate specific antigen secretion in a xenograft model of human prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.***72**, 935-940.
44. Lipinski B. Prostate cancer vaccines, fibrin and selenium: A conceptual review. *Open Prostate Cancer J.* (2010). **3**,69-73.
45. Kralova, V., Brigulova, K., Cervinka, M. and Rudolf, E. (2009). Antiproliferative and cytotoxic effects of sodium selenite in human colon cancer. *Toxicol. In Vitro.* **23**, 1497-1503.